Oncology │ KRAS

KRAS – the key to new treatments in lung and colorectal cancer

The therascreen KRAS RGQ PCR Kit is an FDA-approved companion diagnostic (CDx) test to detect seven mutations in the KRAS oncogene. The test specifically identifies non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) patients that may be eligible for treatment with the following drugs.

Reliably detect the mutations that matter

The therascreen KRAS RGQ PCR Kit is a unique molecular test, based on the detection of specific KRAS mutations in tumor DNA isolated from formalin-fixed paraffin-embedded (FFPE) NSCLC or CRC tumor tissue. The kit targets seven mutations in codons 12 and 13 of the KRAS gene (G12A, G12D, G12R, G12C, G12S, G12V and G13D).

Get the details

Solutions for precision healthcare

QIAGEN’s therascreen kits allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.

Browse our products

Solutions for precision healthcare - KRAS

The therascreen KRAS RGQ PCR Kit is intended for in vitro diagnostic use.